Association of Circulating Tumor Cells and Tumor Molecular Profile With Clinical Outcomes in Patients With Previously Untreated Metastatic Colorectal Cancer: A Pooled Analysis of the Phase III VISNÚ-1 and Phase II VISNÚ-2 Randomized Trials

The bCTC count is a well-established prognostic biomarker in mCRC, as well as in other tumor types. The aim of this analysis was to evaluate the prognostic/predictive role of the bCTC count (≥3 vs.

Saved in:
Bibliographic Details
Published in:Clinical colorectal cancer 2023-06, Vol.22 (2), p.222-230
Main Authors: Jiménez-Fonseca, P., Sastre, J., García-Alfonso, P., Gómez-España, M.A., Salud, A., Gil, S., Rivera, F., Reina, J.J., Quintero, G., Valladares-Ayerbes, M., Safont, M.J., La Casta, A., Robles-Díaz, L., García-Paredes, B., López López, R., Guillot, M., Gallego, J., Alonso-Orduña, V., Diaz-Rubio, E., Aranda, E.
Format: Article
Language:English
Subjects:
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Bevacizumab
BRAF
Clinical Trials, Phase II as Topic
Colonic Neoplasms - drug therapy
Colorectal Neoplasms - drug therapy
Colorectal Neoplasms - genetics
Humans
Metastatic colorectal cancer
Neoplastic Cells, Circulating
Prognosis
Prognostic factors
Randomized Controlled Trials as Topic
RAS
Rectal Neoplasms - drug therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The bCTC count is a well-established prognostic biomarker in mCRC, as well as in other tumor types. The aim of this analysis was to evaluate the prognostic/predictive role of the bCTC count (≥3 vs.
ISSN:1533-0028
1938-0674
DOI:10.1016/j.clcc.2023.02.004